Clene to Present at Upcoming May Conferences
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May.
鹽湖城,2024年5月14日(GLOBE NEWSWIRE)——Clene Inc.(納斯達克股票代碼:CLNN)(及其子公司 “Clene”)及其全資子公司Clene Nanomedicine Inc.,一家處於臨床後期階段的生物製藥公司,專注於改善線粒體健康和保護神經元功能,以治療神經退行性疾病,包括肌萎縮性側索硬化症多發性硬化症和多發性硬化症,今天宣佈將在5月參加以下投資者會議。
Mizuho Neuroscience Summit 2024
Dates: May 20-21, 2024
Location: Boston Harbor Hotel, Boston, MA
Format: Panel Presentations and 1x1 meetings
2024 年瑞穗神經科學峯會
日期:2024 年 5 月 20 日至 21 日
地點:馬薩諸塞州波士頓波士頓海港酒店
形式:小組演講和 1x1 會議
Benchmark 2024 Healthcare House Call Virtual Conference
Dates: May 21-22, 2024
Location: Virtual
Format: 1x1 meetings
Benchmark 2024 醫療保健公司電話會議虛擬會議
日期:2024 年 5 月 21 日至 22 日
地點:虛擬
格式:1x1 會議
Virtual A.G.P. Healthcare Conference
Date: May 22, 2024
Location: Virtual
Format: 1x1 meetings
虛擬 A.G.P. 醫療保健會議
日期:2024 年 5 月 22 日
地點:虛擬
格式:1x1 會議
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
關於 Clene
Clene Inc.(納斯達克股票代碼:CLNN)(及其子公司 “Clene”)及其全資子公司Clene Nanomedicine Inc. 是一家處於臨床後期階段的生物製藥公司,專注於改善線粒體健康和保護神經元功能,以治療神經退行性疾病,包括肌萎縮性側索硬化、帕金森氏病和多發性硬化。CNM-AU8 是一種在研的同類首創療法,它通過靶向線粒體功能和NAD途徑,同時減少氧化應激的機制來提高中樞神經系統細胞的存活率和功能。cnm-au8 是 Clene Nanomedicine, Inc. 的聯邦註冊商標。該公司總部位於猶他州鹽湖城,研發和製造業務位於馬里蘭州。欲了解更多信息,請訪問 www.clene.com 或者關注我們 X(前身爲 Twitter) 和 領英。
Contacts:
聯繫人:
Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 |
Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
媒體聯繫人 伊格納西奧·格雷羅-羅斯,博士,或大衛·舒爾 魯索夥伴有限責任公司 Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 |
投資者聯繫人 凱文·加德納 生命科學顧問 kgardner@lifesciadvisors.com 617-283-2856 |
譯文內容由第三人軟體翻譯。